Rob Michael/LinkedIn
May 16, 2025, 02:14
Rob Michael Announces FDA Approval of AbbVie’s New NSCLC Therapy
Rob Michael, Chief Executive Officer of AbbVie, posted on LinkedIn:
“Today, the U.S. FDA announced accelerated approval for AbbVie’s new medicine to treat certain types of advanced non-squamous non-small cell lung cancer (NSCLC). There is a need for new therapies for patients with difficult to treat tumors like NSCLC given the limited treatment options.
I am proud of our employees’ strong commitment to patients and their extensive efforts to make this approval possible.
Learn more here.”
More posts featuring FDA.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 16, 2025, 02:14
May 16, 2025, 00:23
May 15, 2025, 18:17
May 15, 2025, 17:41
May 15, 2025, 17:00